Search our science

Search our scientific publications and resources
on rare bleeding disorders

Molecule
Study Phase
Content Type


Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.

 

Search Results

We found 359 resources matching your search criteria

Primary manuscript
Rajpurkar M, Croteau S, Boggio L, Copper D. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019;10:335-340.
Primary manuscript
Buckner T, Sidonio R, Witkop M, Guelcher C, Cutter S, Iyer N, Cooper D. Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study. Pat Rel Outcomes Meas. 2019;1-16.
Primary manuscript
Cutter S, Guelcher C, Hunter S, Rotellini D, Dunn S, Cooper D. Mild-Severe Hemophilia B Impacts Relationships for US Adults and Children With Hemophilia B and Their Families: Results From the Bridging Hemophilia B Experiences, Results, and Opportunities Into Solutions (B-HERO-S) Study. Pat Rel Outcomes Meas. 2019;2019:257-266.
Oral presentation
Astermark J, Angchaisuksiri P, Benson G, Castaman G, Chowdary P, Eichler E, Hvitfeldt-Poulsen L, Jimenez Yuste V, Kavakli K, Matsushita T, Oldenburg J, Paroski-Wheeler A, Shapiro, A, Zupancic-Salek S, Young G. Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in haemophilia A and haemophilia A/B with inhibitors: Phase 2 trial results. International Society on Thrombosis and Haemostasis - 27th Congress. 2019;3(S1).
Abstract
Astermark J, Angchaisuksiri P, Benson G, Castaman G, Chowdary P, Eichler E, Hvitfeldt-Poulsen L, Jimenez Yuste V, Kavakli K, Matsushita T, Oldenburg J, Paroski-Wheeler A, Shapiro, A, Zupancic-Salek S, Young G. Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in haemophilia A and haemophilia A/B with inhibitors: Phase 2 trial results. International Society on Thrombosis and Haemostasis - 27th Congress. 2019;3(S1).
Oral presentation
Klamroth R, Feistritzer C, Friedrich U, Lentz SR, Reichwald K, Zak M, Chowdary P. Immunogenicity, safety, pharmacokinetics and preliminary efficacy results from the first human subcutaneous factor VIII trial (subcutaneous turoctocog alfa pegol, SC N8-GP) in previously treated patients with hemophilia A (alleviate 1). ISTH 2019.

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to www.novonordisk.com